The evaluation of vaccine safety involves pre-clinical animal studies, pre-licensure randomized clinical trials and post-licensure safety studies. Sequential design and analysis are of particular interest because they allow early termination of the trial or quick detection that the vaccine exceeds a prescribed bound on the adverse event rate. After a review of recent developments in this area, we propose a new class of sequential generalized likelihood ratio tests for evaluating adverse event rates in two-armed pre-licensure clinical trials and single-armed post-licensure studies. The proposed approach is illustrated using data from the Rotavirus Efficacy and Safety Trial (REST). Simulation studies of the performance of the proposed approach and other methods are also given.
INTRODUCTION
Despite the significant public health impact seen from the introduction of vaccines, the safety of vaccines continues to receive considerable attention, and has raised a variety of issues.
First, the withdrawal of a rotavirus vaccine (a tetravalent rhesus-human reassortant rotavirus vaccine, RRV-TV) in 1999 has raised public concerns on vaccine safety [1] and hence the balance of benefit and risk of a vaccine product. Second, unlike any therapeutic products, vaccines are typically given to healthy people and even to vulnerable populations such as infants and young children. In addition, many vaccines are universally recommended and mandated for schooling and some special programs (e.g., military service), where the tolerance of vaccine risk is low. Hence, ensuring vaccine safety is important in public health activities and policies [2, 3] . [2, 4] . Sequential methods are increasingly used in vaccine clinical trials and post-licensure monitoring, whose goal is quick detection of the association of adverse events that might be caused by the vaccine. Recently, Davis et al. [5] , Lieu et al. [6] and Heyse et al. [7] have proposed to use sequential methods for testing vaccine safety. Though not offered specifically for vaccine safety evaluation, other methods have also been suggested for sequential safety assessment of biopharmaceutical products in clinical trial or post-licensure settings [8, 9, 10, 11, 12] .
In this paper we propose a new class of sequential generalized likelihood ratio (GLR) tests for testing the incidence rates of adverse events in vaccine clinical trials and post-licensure surveillance studies. The paper is organized as follows. Section 2 describes typical design considerations for vaccine safety evaluation. Section 3 reviews sequential GLR tests and other sequential tests that have been applied to test vaccine safety. A key ingredient in our proposed GLR tests for vaccine safety, given in Section 4, is the exponential family representation of the rare event sequence under the commonly assumed model of Poisson arrivals of adverse events. Simulation studies are presented in Section 5 to compare the performance of various sequential testing methods, and Section 6 gives an illustrative example from the Rotavirus Efficacy and Safety Trial. Concluding remarks and discussions on the closely related problem of sequential safety surveillance are presented in Section 7.
DESIGN CONSIDERATIONS FOR VACCINE SAFETY EVALUATION
Safety profiles of vaccine candidates evolve throughout evaluations in laboratories, animals, phased human clinical trials as well as post-marketing monitoring [2, 13] . It is crucial to recognize that vaccines are different from most pharmaceutical products in many ways; understanding these differences is important in designing safety studies of vaccines. First, the safety standard is generally higher for vaccines than for drugs. Unlike therapeutic products, vaccines are usually administered to healthy populations, some of whom may be vulnerable children and infants. Some vaccines are universally recommended and as a result are administered to a large number of people. Hence, "first do no harm" is the widespread acceptable principle in public health and a much lower risk tolerance is expected. Second, given that the duration of observation in pre-licensure clinical trials is often less than 30 days (sometimes 42 days) after vaccination, the rarity of certain serious adverse events often necessitates a large sample size. For example, for the REST study of a rotavirus vaccine [7] , with a background incidence rate of intussusceptions of 1 in 2000 person years and 42 days of post-vaccination follow-up after each of 3 dose vaccinations, a sample of 60,000 subjects is required in order to observe approximately 10 intussusceptions. Third, vaccines are biologically derived and variations in biological activities can occur. This is further complicated by variations in biological manufacturing processes such as formulation, fermentation and virus sensitivity to storage condition, which together contribute to the variability of biologic activities. These factors may contribute to the adverse experience profile of the vaccine. In addition, many vaccines are combinations of multiple active biologic agents and it is generally difficult, if not impossible, to attribute an adverse event to a particular agent. Finally, unlike drugs for which substitute therapies may be available, vaccines prevent significant morbidity and mortality and usually do not have many alternative options. Hence the decision to withdraw a vaccine should be made with extra care according to risk and benefit balance.
Safety assessment of a vaccine is an ongoing process throughout the product's life cycle.
Statistical aspects of design and analysis play an important role in this process. The study design, such as the choice of endpoints, sample size, and study duration, is driven by the objectives, hypotheses, and pre-specified criteria for success, which may vary depending on whether the vaccine is (a) the first vaccine against a particular disease or a vaccine for which a safety issue has been identified for similar vaccine products, or (b) for vulnerable populations, or (c) to be recommended for universal application [2] . Some typical design considerations include the following:
• A meaningful evaluation of the risk of some rare yet serious adverse events to increase the possibility of regulatory approval; this usually requires a large sample size.
• A continuous safety monitoring system to detect increased risk of targeted adverse events as early as possible.
• Criteria for early trial termination due to unsafe outcomes associated with the vaccine during interim monitoring, which would minimize the risk to study participants.
• Immediate communication with the Data and Safety Monitoring Committee when an adverse event is reported.
An example is given in [7] for a rotavirus vaccine trial. The sequential test procedures described in this paper incorporate these design features, as will be explained in the next two sections.
REVIEW OF SEQUENTIAL GENERALIZED LIKELIHOOD RATIO TESTS
The use of likelihood ratios as test statistics in sequential analysis has a long history, dating back to Wald's sequential probability ratio test (SPRT) for testing a simple null hypothesis against a simple alternative hypothesis [14] . Suppose X 1 , X 2 , . . . are independent random variables with a common density f and one is interested in testing H 0 : f = f 0 versus
The SPRT stops sampling at stage
and accepts The thresholds A and B can be approximated by using Wald's approximations to the error probabilities: A ≈ log(α 1−α ), B ≈ log(
1−α α
). Dvoretzky, Kiefer and Wolfowitz [16] extended the SPRT to continuous-time processes with independent increments.
To apply the SPRT to vaccine safety testing, Lieu et al. [6] 
Because in practice it is often difficult to come up with an appropriate choice of ρ for the alternative hypothesis, Lieu et al. [6] maximize (2) over ρ ≥ 1, yieldinĝ
at time t. They propose to use the stopping rulê
and to reject H 0 ifRT ≥ B. They call the test a MaxSPRT and propose to use a truncated version of the test, for which they use Monte Carlo simulations to determine its type I error probability and the power at various alternatives.
For discrete-time observations X 1 , X 2 , . . . from an exponential family of densities f θ (x) = exp{θx − ψ(θ)} with respect to some measure on the real line, more efficient extensions of the SPRT to composite hypotheses than the MaxSPRT have been introduced in the sequential analysis literature. Lai [17] has given a survey of these tests, which are called "sequential generalized likelihood ratio (GLR) tests". First consider the composite null hypothesis H 0 :
θ ≤ θ 0 versus the composite alternative hypothesis H 1 : θ ≥ θ 1 , with θ 0 < θ 1 . The sequential GLR test of H 0 versus H 1 stops sampling at stage
whereθ n is the MLE at stage n, so that the first test statistic in (5) is the GLR statistic for testing θ 0 versus alternatives larger than θ 0 , and the second is that for testing θ 1 versus alternatives smaller than θ 1 . The test rejects H i if the GLR statistic for testing θ i exceeds the threshold B 
, i.e.,
and the test rejects H 0 if and only ifθ τ c > θ 0 , where the function g is the optimal stopping boundary for a continuous-time sequential testing problem associated with an approximating Brownian motion. Note that unlike MaxSPRT that uses the contrained MLE and a timeinvariant threshold in (4), the sequential GLR test for testing
(without an indifference zone) uses the usual GLR statistic (with unconstrained MLE) and a
time-varying threshold e g(cn)
. in the approximation (6) to the
as t → 0, thereby accounting for the time-varying uncertainties in the estimateθ n of θ as t = cn varies from 0 to ∞.
In the context of conventional clinical trials, even when a sequential design is used to allow early stopping for safety, there is usually an upper bound M on the sample size due to limits on time and resources and to risk-benefit considerations (e.g., when the vaccine is strongly efficacious or when the disease can be fatal). Lai and Shih [21] have pointed out that this upper bound M on the sample size implicitly assumes an alternative θ 1 in testing the one-sided null hypothesis H 0 : θ ≤ θ 0 at significance level α. Specifically, the fixed sample test that (5) is more appropriate than the commonly used group sequential designs for testing of treatment efficacy. In fact, Lieu et al. [6] even assume continuous-time rather than discrete-time data in their stopping rule (4).
In the next section we show how the continuous-time information can be represented so that the stopping rule (5) suffices for efficient designs. Note that unlike (5), the SPRT and the MaxSPRT do not have bounded stopping rules. Recognizing this, Lieu et al. [6] consider a variant of (4) that stops the trial at timeT = min(T , t * ) and rejects H 0 ifRT ≥ B, accepting
The sequential GLR test with stopping rule (5) can be readily extended to treat more complex composite hypotheses involving multivariate parameters, as shown in Section 3.4 of [21] . Specifically, consider a multiparameter exponential family of densities f θ (x) = exp(θ for every fixed θ, the sequential GLR test of H 0 versus H 1 stops sampling at stage
whereθ n is the MLE of θ at stage n and Λ n,j are the GLR statistics at stage n:
Because the signed-root likelihood ratio statistic
behaves like a normal random walk under u(θ) = u j , j = 0, 1, we can approximate l n,j by a sum of independent standard normal random variables under u(θ) = u j and thereby determine
n . In single-armed post-licensure studies in which covariates such as age and vaccination rates may substantially affect adverse event rates, we can use this kind of sequential GLR tests to incorporate covariate adjustments.
EXPONENTIAL FAMILY MODELS OF ADVERSE EVENTS AND ASSOCIATED SEQUENTIAL GLR TESTS

Adverse events in single-armed post-licensure studies
The single-armed study described by Davis et al. [5] is a retrospective study that uses data that the study wants to detect, e.g., p 1 = 2p 0 . Davis et al. [5] propose to use the SPRT to test H 0 versus H 1 based on the independent binomial random variables X i with density function proportional to p X i (1 − p) n i −X i , which belongs to an exponential family with natural parameter θ = log(p/(1 − p)).
As described above, Lieu et al. [6] use the number N t of adverse events in a cohort of vaccinated subjects for sequential testing of vaccine safety. Instead of N t , which they assume to be a Poisson process, we can work with the inter-arrival times X i between successive adverse events. These are independent exponential random variables with means ξ i . First assume that µ t = λt and therefore all the ξ i are equal to ξ = 1/λ. The X i belong to the exponential family
with natural parameter θ = −λ. The SPRT for testing H 0 : λ ≤ λ 0 versus
where
Since the MLE isλ n = n/S n , the stopping rule of the MaxSPRT iŝ 
The more general case in which X i ∼ Exp(λ i ) have rates λ i varying with i, as in [6] , can be converted back to the i.i.d. case by considering
Adverse events in pre-licensure randomized clinical trials
Consider a clinical trial in which patients are randomized to receiving vaccine or placebo.
Assume that the arrivals of adverse events follow a Poisson process, with rate λ V for vaccine (V) and λ C for placebo (C) recipients. This assumption will be relaxed later by allowing the rates to vary with time. When an event occurs, it is associated with either V or C and pr( V | event occurs at time t after previous one) = 
The goal of a pre-licensure randomized clinical trial is to show that the vaccine product is effective and safe. The safety objective can be formulated as testing
In view of (11), the likelihood ratio statistic for testing 
The SPRT for testing H 0 :
where l n = n i=1 {δ i log(
)} and a < 0 < b. The SPRT does not have a bounded stopping rule. The GLR statistic for testing p j (j = 0, 1) has logarithm
The truncated MaxSPRT has stopping ruleT = min{T , n * }, wherê
and rejects H 0 if lT ,0 ≥ b. The stopping rule (5) of the sequential GLR test is
The stopping rule (14) is bounded above by n * , where n * is the smallest integer n such that
whose common value is denoted by I(p * ). Note that (14) introduces a lower boundary into (13) to allow early stopping for "futility" in the sense that the vaccine is unlikely to be shown unsafe by the prescheduled end of the trial (after observing n * adverse events).
IMPLEMENTATION AND SIMULATION STUDIES
For a given type I error probability α and type II error probabilityα, the thresholds in the stopping rule of the SPRT can be approximated by using Wald's approximations reviewed Table I gives the expected number of adverse events and power for the SPRT,
MaxSPRT and the sequential GLR test, whose stopping rules are given by (7)- (9). The SPRT and MaxSPRT are truncated at 1000 events. To determine the thresholds of the stopping rules, the boundary crossing probabilities of the SPRT are obtained by Wald's approximations, and those of MaxSPRT and the sequential GLR test are computed by Monte Carlo using 100,000
simulations. Each result in Table I is based on 50,000 simulations. The SPRT is optimal when the assumed alternative value γ in the likelihood ratio statistic is equal to the actual
The sequential GLR test has comparable expected number of events and power at these values of λ V /λ C , except for the case λ V /λ C = 2, where the sequential GLR test has half the expected number of events but also much less power since λ V /λ C falls substantially below the lower bound 3 specified by H 1 . In contrast, MaxSPRT requires substantially larger expected number of events at λ V /λ C = 1 or 2. The maximum number of events is 28 for the sequential GLR test, which is much smaller than 1000 for the truncated SPRT or MaxSPRT.
INSERT Consider a two-armed pre-licensure randomized study to test
λ V /λ C ≥ 3, with prescribed Type I error probability α = 0.05 and Type II error probabilitỹ Table II gives the expected number of events and power for the SPRT, MaxSPRT and the sequential GLR test, whose stopping rules are given by (12)- (14) .
The SPRT and MaxSPRT are truncated at 1000 or 100 events (2 cases); 100 is the maximum number of events for the sequential GLR test. To determine the thresholds of the stopping rules, the boundary crossing probabilities of the SPRT are obtained by Wald's approximations, and those of MaxSPRT and the sequential GLR test are computed by using a recursive numerical algorithm described in the Appendix. Table II , whose results are computed by the recursive numerical algorithm, shows the superior performance of the sequential GLR test in two-armed randomized trials, similar to the results in Table I for single-armed post-licensure studies.
INSERT were randomized at a 1:1 ratio to receive either three doses of RV5 or placebo. All infants were monitored for adverse events during the entire trial duration. The primary safety hypothesis was that RV5 would not increase the risk of intussusception, relative to placebo, within 42 days after any dose. This concern of potential increased risk of intussusception, which is a serious yet uncommon illness with a background incidence rate of 18-56 cases per 100,000 infant years during the first year of life, stems from the withdrawal of a tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) in October 1999 when the post-licensure safety surveillance revealed a substantial short-term increase in the risk of intussusception among RRV-TV recipients, primarily in the exposure window 3 -14 days after the first dose [1, 22] . Details of the REST study design are given in [7] and [23] .
Assuming that intussusception occurrences follow a Poisson process, with rate λ V for vaccine recipients and λ C for placebo recipients, as in Section 4.2, Heyse et al. [7] made use of the fact that conditional on the total number n of intussusception cases from both groups, the number of intussusception cases in the vaccine group is Binomial(n, p), where
. They therefore applied a repeated significance test that terminates the study after observing a total of n intussusception cases from both groups and declares the vaccine to be unsafe if
where # n (V ) denotes the number of intussusception cases in the vaccine group among the n intussusception cases. The study is also terminated and declares the vaccine to have a clinically acceptable safety profile if
where p 1 = 10/11, corresponding to a 10-fold increase in risk for the vaccine group. Although the nominal significance level of 0.025 in (15) or (16) does not adjust for repeated analysis of the accumulated data, Monte Carlo simulations (involving 10000 random sequences) showed that the probability for the study to stop with a positive conclusion regarding vaccine safety is 0.94 for a vaccine with no increased risk of intussusception, and the probability for the study to declare the vaccine to be unsafe is almost 1 for relative risks of 6 or greater [7] . This conservative approach is appropriate given the nature of the safety evaluation. Section 4.2 provides a methodological innovation that leads to independent Bernoulli random variables without conditioning on the total number of events, thereby making conventional sequential tests directly applicable (to these independent Bernoulli observations).
During the study, all suspected cases of intussusception were promptly reported to, and adjudicated by, an independent, blinded adjudication committee. The study stopped enrollment upon the recommendation of the Data and Safety Monitoring Board (DSMB) when about 70,000 infants had completed their follow-up. At that time, there were 11 confirmed cases of intussusception, 6 in the vaccine group and 5 in the placebo group. Figure 1 summarizes the sequentially accumulated data and the boundaries of (a) the repeated significance test (15)- (16) and (b) the sequential GLR test (14) . Here p 0 = 1/2 and p 1 = 10/11. The lower boundary of the repeated significance test was crossed and the DSMB recommended to stop the study. If the sequential GLR test (14) had been used instead, the lower boundary would also have been crossed at the same time.
INSERT FIGURE 1 ABOUT HERE
In the REST study, the lower "safe" boundary actually used a group sequential design for the DSMB to conduct interim analysis, starting with a minimum of 60,000 infants and subsequent groups of 10,000 infants. Therefore stopping at the lower boundary involves the total number of intussusception cases of the vaccine and placebo recipients up to the time of each interim analysis. The implementation methods described in Section 5 can be easily modified to handle this situation.
DISCUSSION
As noted by Lai [24, p.311] , although refinements and modifications of Wald's SPRT for the design of clinical trials had been developed in the 1950s, they received little attention from the biomedical community until the Beta-Blocker Heart Attack Trial (BHAT). The main reason for this lack of interest is that the sample size for a typical trial is too small to allow further reduction while still maintaining reasonable power at the alternatives of interest. BHAT, whose endpoint is time to failure, drew immediate attention to the benefits of sequential methods not because it reduced the number of subjects but because it shortened a four-year study by 8 months in periodic reviews of the patients accrued. The success of BHAT led to the development and increasing use of group sequential designs in phase III clinical trials, beginning with the influential work of Lan and DeMets [25] that introduced a "type I error spending function" to modify a truncated, fully sequential procedure into a group sequential procedure. The development of vaccine safety tests in the past few years seems to have given fully sequential methods a surge of interest that had been lacking in clinical trials since the 1950s.
The design considerations for vaccine safety evaluation described in Section 2 pave the way for adopting fully sequential tests, beginning with the application of the SPRT by Davis et al.
[5] described at the end of Section 4.1. Subsequently Lieu et al. [6] introduced the MaxSPRT.
In Section 3 we have provided an overview of sequential tests of composite hypotheses, showing in particular that the truncated version of MaxSPRT, which has been applied in [6] to postlicensure vaccine safety monitoring, is in fact a sequential GLR test without a lower boundary.
As noted in [21] and illustrated in Examples 1 and 2, when a sequential test is truncated, introducing a suitable lower boundary can lead to substantial savings in sample size with little loss of power.
For rare adverse events following vaccination (V) or placebo (C) injection, the effective sample size is the total number of adverse events in the sample of a large number of subjects accrued over a number of years. In Section 4.2 we have shown how this effective sample size can be used to develop an efficient sequential test comparing the event rates of the V and C treatments in a pre-licensure randomized clinical trial. Since the design is informationbased, one can adjust, without altering the type I and II error probabilities, the total number of subjects accrued per year and the number of years as the trial progresses, based on the observed adverse event rate of the combined V and C groups as the trial progresses.
The sequential post-licensure studies considered in this paper are either of the type considered by Davis et al. [5] or in Phase IV studies, for which the study design typically has a maximum sample size and aims at testing the null hypothesis that the adverse event rate for the vaccinated subjects does not exceed the baseline rate. Another approach to post-licensure vaccine safety monitoring is sequential surveillance, which does not have a maximum sample size and continues until the vaccine is no longer used because of safety or efficacy issues. The analog of the type I error probability of a sequential test is the false alarm rate of a sequential surveillance procedure. One such procedure that has been considered for surveillance in public health is Page's [26] CUSUM (cumulative sum) method; see [27, 28] . Because the CUSUM rule originated from applications to quality control, there are serious limitations in its application to post-licensure vaccine safety surveillance. For example, quality control charts use average run lengths (ARL), which are the expected durations to giving an alarm, for their operating characteristics, and the threshold of a CUSUM chart is determined by the ARL to false alarm. The past two decades have witnessed important breakthroughs and major advances in sequential surveillance that has moved far beyond the CUSUM method; see [29, 30, 31] and the references therein. In particular, the ARL to false alarm is replaced by a more flexible false alarm rate in [29] , in which more versatile sequential detection and surveillance methods are introduced to replace the CUSUM rule, which like the SPRT, requires complete specification of the baseline and post-change parameters. These methods include the sequential GLR detection rules, which have been extended in [31] to tackle the case where both the baseline and post-change parameters are unknown. Moreover, a theory of sequential surveillance, comparable to the relatively complete theory of sequential detection, is introduced in [30] for exponential families. While sequential testing can be used to test if the adverse event rate of a large cohort of vaccinated subjects in a post-licensure study differs from the baseline rate, sequential surveillance can be used to detect elevated risks due to environmental, viral or other changes that have affected the approved vaccine's safety and efficacy, or for certain sub-populations with previously undetected risk factors.
Find the solution p * ∈ (p 0 , p 1 ) of the equation
and let I * denote the common value on either side of the equation. The type I and type II error probabilities can be expressed as
, respectively, where n * is the smallest integer n such that nI * ≥ max(b 0 , b 1 ). We use the following recursive algorithm to 
